The Asthma Drug Class That Just Can't Catch a Break

Early candidates like MK-886 and MK-591 showed promise in early clinical studies, including human allergen challenge trials, but never made it through full clinical development, with companies declining to publish their reasons for stopping. GSK licensed FLAP inhibitors from Amira Pharmaceuticals back in 2008 and eventually advanced a candidate called fiboflapon into a phase 2 asthma study.

Another GSK candidate, GSK2190915, made it further but hit a paradox that haunts this entire drug class. In a trial of patients with refractory asthma, the drug successfully crushed its biochemical target: it suppressed leukotriene B4 (a key inflammatory molecule) by more than 90%. On paper, that's a home run. But the patients didn't actually get better. Their sputum neutrophils didn't drop, and their symptoms didn't meaningfully improve.

In other words, the drug did exactly what it was designed to do at the molecular level, and it still didn't matter clinically. That's the kind of failure that makes scientists question whether they truly understand the biology.

Why This Matters Beyond One Drug

Atuliflapon's failure raises a fundamental question: is the FLAP target itself the problem, or has nobody found the right way to hit it?

The optimistic view is that better drug design, different patient populations, or longer trials could eventually crack the code. Atuliflapon showed strong pharmacodynamic properties in early studies, demonstrating dose-dependent leukotriene inhibition in healthy volunteers. The biology was responding. The clinical outcomes just didn't follow.

The pessimistic view is more sobering. Asthma is a complex disease driven by multiple overlapping pathways. Blocking one pathway (even blocking it really well) may simply not move the needle enough for patients whose inflammation has several other drivers. It's like trying to stop a flood by plugging one hole in a dam that has a dozen leaks.

For now, montelukast remains the dominant leukotriene-targeting therapy for asthma. It works by blocking the CysLT1 receptor rather than inhibiting FLAP, and while it's far from perfect (the FDA has flagged neuropsychiatric side effects, and it's generally less effective than adding a long-acting beta-agonist to inhaled steroids), it has the advantage of actually being on the market. Once-daily oral dosing and a relatively clean safety profile keep it entrenched in treatment guidelines as an add-on option for mild-to-moderate asthma.

AstraZeneca's Respiratory Bench Isn't Empty

The good news for AstraZeneca is that atuliflapon wasn't carrying the respiratory franchise on its shoulders. The company has a deep roster of marketed products and late-stage candidates that don't depend on FLAP biology.

TEZSPIRE (tezepelumab), which blocks a protein called TSLP that sits even further upstream in the inflammatory cascade, is being studied in the WAYFINDER trial to see if it can help patients reduce their oral corticosteroid use. FASENRA (benralizumab) continues generating long-term data in eosinophilic diseases. BREZTRI, an inhaled triple therapy, is building evidence in COPD patients with cardiovascular risk. And AIRSUPRA (albuterol/budesonide) is positioned as a next-generation rescue inhaler that fights inflammation while relieving symptoms.

AstraZeneca has also signaled a broader strategic shift toward biologics and disease modification rather than traditional small-molecule approaches. The company is investing in machine learning to predict disease progression in conditions like idiopathic pulmonary fibrosis and COPD. Losing atuliflapon hurts, but it doesn't derail the strategy.

The Bigger Picture

The FLAP inhibitor story is a cautionary tale about one of drug development's cruelest tricks: hitting your target perfectly and still failing the patient. GSK saw it. AstraZeneca just saw it again. The leukotriene pathway clearly matters in asthma; decades of research confirm that. But translating upstream pathway inhibition into the kind of meaningful clinical improvements that regulators (and patients) demand has proven stubbornly elusive.

Somewhere, a scientist is probably already sketching out the next attempt. FLAP remains a biologically rational target, and the unmet need in asthma is real; current therapies leave many patients with inadequate control. But after this many swings and misses, the next company to step up to the plate will need a very compelling reason to believe their bat is different.

For now, the FLAP inhibitor clubhouse remains empty. And the door is still locked.

Erasca Hit a Home Run. The Stock Fell 47%.

Erasca's pan-RAS inhibitor posted jaw-dropping early cancer data that analysts called a "home run." Then the stock fell 42% in a single day. A patient death, a patent fight, and transparency questions collided with the best data in Erasca's history.